Amobee, a digital advertising company owned by SingTel, has acquired Gradient X, a Santa Monica, Calif.–based real-time bidding platform. No financial terms were disclosed. Gradient X has raised around $4 million in VC funding from Rincon Venture Partners, GRP Partners, Crosscut Ventures, Siemer Ventures, Founder Collective, Baroda Ventures and individual angels. www.gradientx.com
Bunge Ltd. (NYSE: BG) has agreed to sell its 50% stake in its Moroccan fertilizer joint venture (Bunge Maroc Phosphore) to JV partner OCP Group. No financial terms were disclosed.www.ocpgroup.ma
Suntory Beverage & Food Ltd. (Tokyo: 2587) is in “advanced talks” to buy the LucozadeandRibena beverage brands of GlaxoSmithKline (LSE: GSK) for more than 1 billion, according to Reuters. An agreement could be announced within the next several days. www.suntory.com
Braintree, a Chicago-based payment platform for online and mobile commerce, is shopping itself to potential acquirors with a $1 billion asking price, according to TechCrunch. So far it has held discussions with such companies as PayPal and Square. Braintree has raised $70 million in VC funding from firms like Accel Partners and New Enterprise Associates. www.braintreepayments.com
Acceleron Pharma Inc., a Cambridge, Mass.-based developer of protein therapeutics for cancer and rare diseases, has set its IPO terms to 4.65 million shares being offered at between $13 and $15 per share. It would have an initial market cap of approximately $360 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol XLRN, with Citigroup and Leerink Swann serving as co-lead underwriters. Shareholders include Polaris Venture Partners (15.6% pre-IPO stake), Venrock Partners (12.4%), Advanced Technology Ventures (12.5%), Celgene Corp. (12.3%), Flagship Ventures (11.1%), OrbiMed Advisors (10.6%), Bessemer Venture Partners, Alkermes, Avalon Ventures and Sutter Hill Ventures. www.acceleronpharma.com
BenefitFocus Inc., a Charleston, S.C.-based provider of cloud-based benefits software for consumers, employers and brokers, has set its IPO terms to 4.5 million shares being offered at between $21.50 and $24.50 per share. It would have an initial market cap of approximately $559 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol BNFT, with GoldmanSachs, Deutsche Bank and Jefferies serving as lead underwriters. Shareholders include Goldman Sachs (65.95% pre-IPO stake) and Oak Investment Partners (11.45%).www.benefitfocus.com
Bind Therapeutics Inc., a Cambridge, Mass.-based nanomedicines company, has set its IPO terms to 4.7 million shares being offered at between $14 and $16 per share. It would have an initial market cap of approximately $237 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol BIND, with Credit Suisse and Cowen & Co. serving as lead underwriters. Shareholders include Polaris Venture Partners (18% pre-IPO stake), Flagship Ventures (13.9%), Rusano (11.5%), DHK Investments (8.6%), Arch Venture Partners (8.5%) and NanoDimension (6%). www.bindtherapeutics.com
Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com
